Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST: Shingrix Booster in Solid-Organ Transplant Recipients
NCT07443709Phase 2Not yet recruiting
- Sponsor
- Oriol Health Care
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by Oriol Health Care. Primary endpoint: Proportion of participants with >=2-fold increase in anti-gE antibody titers from baseline at 4 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07443709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443709.